|

A Multicenter, Open-Label, Single-Arm Extension Study to Evaluate the Safety and Efficacy of FURESTEM-OA-Kit Inj. in Knee Osteoarthritis Patients Who Received Placebo in the K0701 Phase 2a Trial

RECRUITINGSponsored by Kang Stem Biotech Co., Ltd.
Actively Recruiting
SponsorKang Stem Biotech Co., Ltd.
Started2026-07-20
Est. completion2031-12-31
Eligibility
Age19 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07754175

Summary

A Multicenter, Open-Label, Single-Arm Extension Study to Evaluate the Safety and Efficacy of FURESTEM-OA-Kit Inj. in Knee Osteoarthritis Patients Who Received Placebo in the K0701 Phase 2a Trial

Eligibility

Age: 19 Years+Healthy volunteers accepted
Inclusion Criteria:

* Participants who received placebo in the K0701 clinical trial and completed the Long-term follow-up study
* Participants who voluntarily provide written informed consent to participate in this extension study

Exclusion Criteria:

Participants meeting any of the following criteria:

* Participants whom the investigator considers unsuitable for participation in this extension study.
* Pregnant or breastfeeding women, and women of childbearing potential or men who do not agree to use an appropriate method of contraception during the study

Conditions2

ArthritisKnee Osteoarthritis

Browse More Trials

Arthritis trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.